Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21154444 | 0.89 | PTPN11 (0.58) | PTPN11KCNH2EGFR | |
| SCHEMBL23186853 | 0.87 | PTPN11 (0.71) | PTPN11 | |
| SCHEMBL19785587 | 0.87 | PTPN11 (0.61) | PTPN11KCNH2 | |
| SCHEMBL25514897 | 0.87 | PTPN11 (0.59) | PTPN11KCNH2EGFR | |
| SCHEMBL30295918 | 0.87 | PTPN11 (0.61) | PTPN11KCNH2 | |
| SCHEMBL23083845 | 0.86 | PTPN11 (0.54) | PTPN11KCNH2EGFR | |
| SCHEMBL23083492 | 0.86 | PTPN11 (0.54) | PTPN11KCNH2EGFR | |
| SCHEMBL23083851 | 0.86 | PTPN11 (0.54) | PTPN11KCNH2EGFR | |
| SCHEMBL23186850 | 0.85 | PTPN11 (0.55) | PTPN11KCNH2EGFR | |
| SCHEMBL30296051 | 0.83 | PTPN11 (0.81) | PTPN11KCNH2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3484856-B1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2018013597-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |